Summary Keryx has been marketing Auryxia off label conveying a “two for one benefit”. An “iron benefit” is absolutely critical to the successful marketing of the drug, but Auryxia has not been approved for this. Keryx has even marketed the detailed financial savings involved from this unapproved indication. Similar illegal marketing practices by Aegerion quickly…

Read More